Compare Oklo Inc (OKLO) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Oklo Inc trades at $34.66 (market cap $6.43B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 9.1× Oklo Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 32 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| OKLO | TAK | |
|---|---|---|
Market Cap | $6.43B | $58.74B |
Volume | 16,238,368 | 3,110,994 |
Sector | Utilities | Health |
52-Week High | $174.14 | $19.05 |
52-Week Low | $34.57 | $13.23 |
Typical Hold Time | 32 Days | 1 Days |
Enterprise Value | $3.97B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.65, down 5.91% today, with a bearish technical signal from moving averages. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Analyst consensus remains strongly bullish with a $78.63 price target, but recent news highlights competitive pressures and dilution concerns from stock sales.
The outlook hinges on OKLO's ability to commercialize its nuclear reactor pipeline. High institutional buy ratings suggest long-term potential, but execution risks, cash burn, and intense competition in the SMR space pose significant challenges. The stock offers speculative growth exposure amid substantial operational and financial headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
